Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167618 · ClinicalTrials.gov registry record · Phase 1
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
A Phase 1 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04167618: Clinical Trial Phase 1 study, sponsored by Y-mAbs Therapeutics.
NCT04167618 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04167618, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
Primary Outcome
Summary of DLTs in DLT evaluable subjects.
Interventions
- DRUG 177Lu-DTPA-omburtamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2022-08-11 |
| Phase | Phase 1 |
Why NCT04167618 stopped before completion
NCT04167618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which 177Lu-DTPA-omburtamab is the first listed.
NCT04167618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04167618 about?
NCT04167618 is a clinical study titled "177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma". Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
What is the current status of trial NCT04167618?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2021-09-30. Estimated completion is 2022-08-11.
What interventions are being tested in trial NCT04167618?
The interventions under investigation include: 177Lu-DTPA-omburtamab (DRUG).
Who is sponsoring clinical trial NCT04167618?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04167618's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI